Authors: J.D. Heidel, J.Y-C. Liu, R.K. Zeidan, Y. Liang, S. Rele, M.E. Davis
Affilation: Calando Pharmaceuticals, United States
Pages: 336 - 337
Keywords: siRNA, deliery, RRM2, nanoparticle, transferrin
Calando Pharmaceuticals is developing siRNA-containing nanoparticle formulations, and its leading formulation that will enter the clinic in 2008 contains the human transferrin protein as a targeting ligand and siRNA targeting the M2 subunit of ribonucleotide reductase (RRM2). Critical parameters in the formulation and function of this therapeutic system will be highlighted using data from pre-clinical investigations. Anti-tumor efficacy is enhanced when the targeted version of the nanoparticles are employed, and results from numerous safety and efficacy studies will be discussed.
Nanotech Conference Proceedings are now published in the TechConnect Briefs